RecruitingPhase 2NCT06408246

ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression

Accelerating Cognition-guided Signatures to Enhance Translation in Depression Aim 3: Clinical Cognitive Trial


Sponsor

Stanford University

Enrollment

162 participants

Start Date

Mar 3, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to understand how a psychotropic medication called guanfacine affects brain network functioning in humans, and how this function interacts with cognitive impairments in people experiencing depressive symptoms.


Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial tests a computerized cognitive training program in people with major depression. The goal is to see whether improving thinking and memory skills (which are often affected by depression) can lead to better overall treatment outcomes for depression. **You may be eligible if...** - You are 18 to 60 years old - You have a current diagnosis of major depressive disorder (MDD), confirmed through an interview - You are fluent and literate in English - You are not experiencing psychosis **You may NOT be eligible if...** - You have bipolar disorder or another condition that explains your depression symptoms - You have a severe substance use disorder - You are currently taking certain other medications that might interfere with the study - You have neurological conditions affecting cognitive function Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGuanfacine

Guanfacine immediate release is an established and safe FDA-approved treatment that acts directly by stimulating α2A adrenoceptors.

DRUGSertraline

Sertraline is a well-tolerated FDA-approved antidepressant that is among the most widely prescribed medications for depression.


Locations(2)

Stanford Psychiatry and Behavioral Sciences Department

Palo Alto, California, United States

University of Illinois at Chicago

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06408246


Related Trials